piracetam has been researched along with Anxiety in 24 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study investigates a potential additive neuroprotective effect of levetiracetam combined with hypothermia after hypoxia-induced brain injury in neonatal mice." | 7.83 | Dose-dependent effects of levetiracetam after hypoxia and hypothermia in the neonatal mouse brain. ( Bendix, I; Bertsche, A; Fandrey, J; Felderhoff-Mueser, U; Hoeber, D; Kluever, V; Lueckemann, L; Strasser, K; Thavaneetharajah, S, 2016) |
| "The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy." | 7.79 | Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. ( Arnold, S; Brandt, C; Elger, CE; Hagemann, A; May, TW; Nieder, E; Pohlmann-Eden, B; Schulze-Bonhage, A; Straub, HB; Tergau, F; Witte-Bölt, K, 2013) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 7.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| "Levetiracetam (LEV) has been considered to undergo no significant change in bioavailability during pregnancy; however, it was recently demonstrated to display modifications leading to a drop in its serum level." | 7.74 | Impending status epilepticus and anxiety in a pregnant woman treated with levetiracetam. ( Hubschmid, M; Michel, P; Novy, J; Rossetti, AO, 2008) |
| ") were determined on anxiety induced in female NMRI mice by withdrawal from 21 days of chronic administration of chlordiazepoxide." | 7.71 | The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice. ( Gower, AJ; Klitgaard, H; Lamberty, Y, 2002) |
| "Efficacy results are reported for all seizure types [intention-to-treat (ITT) population, N = 217] and subpopulations with tonic-clonic (n = 152), myoclonic (n = 121), and/or absence (n = 70) seizures at baseline." | 6.77 | Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. ( Delanty, N; Jones, J; Tonner, F, 2012) |
| "Levetiracetam (LEV) is a unique, effective, relatively safe antiepileptic drug that preferentially interacts with synaptic vesicle protein 2A (SV2A)." | 5.42 | Omega 3 polyunsaturated fatty acids enhance the protective effect of levetiracetam against seizures, cognitive impairment and hippocampal oxidative DNA damage in young kindled rats. ( Abdel-Wahab, BA; Habeeb, SM; Khateeb, MM; Shaikh, IA, 2015) |
| " This study investigates a potential additive neuroprotective effect of levetiracetam combined with hypothermia after hypoxia-induced brain injury in neonatal mice." | 3.83 | Dose-dependent effects of levetiracetam after hypoxia and hypothermia in the neonatal mouse brain. ( Bendix, I; Bertsche, A; Fandrey, J; Felderhoff-Mueser, U; Hoeber, D; Kluever, V; Lueckemann, L; Strasser, K; Thavaneetharajah, S, 2016) |
| "The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy." | 3.79 | Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. ( Arnold, S; Brandt, C; Elger, CE; Hagemann, A; May, TW; Nieder, E; Pohlmann-Eden, B; Schulze-Bonhage, A; Straub, HB; Tergau, F; Witte-Bölt, K, 2013) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 3.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| "Levetiracetam (LEV) has been considered to undergo no significant change in bioavailability during pregnancy; however, it was recently demonstrated to display modifications leading to a drop in its serum level." | 3.74 | Impending status epilepticus and anxiety in a pregnant woman treated with levetiracetam. ( Hubschmid, M; Michel, P; Novy, J; Rossetti, AO, 2008) |
| " Elevated plus-maze and passive-avoidance apparatus served as the exteroceptive behavioral models, and diazepam-, scopolamine-, and aging-induced amnesia served as the interoceptive behavioral models." | 3.72 | Ascorbic Acid: a promising memory-enhancer in mice. ( Dhingra, D; Parle, M, 2003) |
| ") were determined on anxiety induced in female NMRI mice by withdrawal from 21 days of chronic administration of chlordiazepoxide." | 3.71 | The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice. ( Gower, AJ; Klitgaard, H; Lamberty, Y, 2002) |
| "Efficacy results are reported for all seizure types [intention-to-treat (ITT) population, N = 217] and subpopulations with tonic-clonic (n = 152), myoclonic (n = 121), and/or absence (n = 70) seizures at baseline." | 2.77 | Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. ( Delanty, N; Jones, J; Tonner, F, 2012) |
| "The levetiracetam XR treatment group showed significantly fewer consequences than did the placebo group during the maintenance period (p = 0." | 2.77 | A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. ( A Tompkins, D; Brunette, MF; Ciraulo, D; Devine, E; Falk, DE; Fertig, JB; Green, AI; Johnson, B; Kampman, K; Litten, RZ; Mattson, ME; Pettinati, H; Ransom, J; Rickman, WJ; Ryan, ML; Scott, C; Stout, R; Strain, EC; Tiouririne, NA, 2012) |
| "Levetiracetam was independently associated with anger/aggression, nervousness/agitation, upset stomach, depression, and sleep disturbance; lamotrigine with nervousness/agitation, upset stomach, and difficulty concentrating; and valproic acid with upset stomach and shaky hands." | 1.43 | Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016) |
| "Levetiracetam (LEV) is a unique, effective, relatively safe antiepileptic drug that preferentially interacts with synaptic vesicle protein 2A (SV2A)." | 1.42 | Omega 3 polyunsaturated fatty acids enhance the protective effect of levetiracetam against seizures, cognitive impairment and hippocampal oxidative DNA damage in young kindled rats. ( Abdel-Wahab, BA; Habeeb, SM; Khateeb, MM; Shaikh, IA, 2015) |
| "Levetiracetam was therefore further examined in another widely used animal model of anxiety, the Vogel conflict test." | 1.32 | Anxiolytic profile of the antiepileptic drug levetiracetam in the Vogel conflict test in the rat. ( Falter, U; Gower, AJ; Klitgaard, H; Lamberty, Y, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Zwierzyńska, E | 1 |
| Pietrzak, B | 1 |
| Kovalev, GI | 1 |
| Kondrakhin, EA | 1 |
| Salimov, RM | 1 |
| Neznamov, GG | 1 |
| Abdel-Wahab, BA | 1 |
| Shaikh, IA | 1 |
| Khateeb, MM | 1 |
| Habeeb, SM | 1 |
| Kowski, AB | 1 |
| Weissinger, F | 1 |
| Gaus, V | 1 |
| Fidzinski, P | 1 |
| Losch, F | 1 |
| Holtkamp, M | 1 |
| Strasser, K | 1 |
| Lueckemann, L | 1 |
| Kluever, V | 1 |
| Thavaneetharajah, S | 1 |
| Hoeber, D | 1 |
| Bendix, I | 1 |
| Fandrey, J | 1 |
| Bertsche, A | 1 |
| Felderhoff-Mueser, U | 1 |
| Novy, J | 1 |
| Hubschmid, M | 1 |
| Michel, P | 1 |
| Rossetti, AO | 1 |
| Phillips, KA | 1 |
| Menard, W | 1 |
| Takahashi, E | 1 |
| Niimi, K | 1 |
| Itakura, C | 1 |
| Delanty, N | 1 |
| Jones, J | 1 |
| Tonner, F | 1 |
| Fertig, JB | 1 |
| Ryan, ML | 1 |
| Falk, DE | 1 |
| Litten, RZ | 1 |
| Mattson, ME | 1 |
| Ransom, J | 1 |
| Rickman, WJ | 1 |
| Scott, C | 1 |
| Ciraulo, D | 1 |
| Green, AI | 1 |
| Tiouririne, NA | 1 |
| Johnson, B | 1 |
| Pettinati, H | 1 |
| Strain, EC | 1 |
| Devine, E | 1 |
| Brunette, MF | 1 |
| Kampman, K | 1 |
| A Tompkins, D | 1 |
| Stout, R | 1 |
| Samotrueva, MA | 1 |
| Tyurenkov, IN | 1 |
| Teplyi, DL | 1 |
| Serezhnikova, TK | 1 |
| Khlebtsova, EB | 1 |
| Surina, NM | 1 |
| Kalinina, TS | 1 |
| Volkova, AV | 1 |
| Malikova, LA | 1 |
| Poletaeva, II | 1 |
| Rayevsky, KS | 1 |
| Fedotova, IB | 1 |
| Bhandari, HS | 1 |
| Hagemann, A | 1 |
| May, TW | 1 |
| Nieder, E | 1 |
| Witte-Bölt, K | 1 |
| Pohlmann-Eden, B | 1 |
| Elger, CE | 1 |
| Tergau, F | 1 |
| Schulze-Bonhage, A | 1 |
| Straub, HB | 1 |
| Arnold, S | 1 |
| Brandt, C | 1 |
| Maschio, M | 1 |
| Dinapoli, L | 1 |
| Sperati, F | 1 |
| Pace, A | 1 |
| Fabi, A | 1 |
| Vidiri, A | 1 |
| Pompili, A | 1 |
| Carapella, CM | 1 |
| Lamberty, Y | 2 |
| Falter, U | 1 |
| Gower, AJ | 2 |
| Klitgaard, H | 2 |
| Parle, M | 1 |
| Dhingra, D | 1 |
| Ciesielski, AS | 1 |
| Samson, S | 1 |
| Steinhoff, BJ | 1 |
| Szalma, I | 1 |
| Kiss, A | 1 |
| Kardos, L | 1 |
| Horváth, G | 1 |
| Nyitrai, E | 1 |
| Tordai, Z | 1 |
| Csiba, L | 1 |
| Siniscalchi, A | 1 |
| Gallelli, L | 1 |
| De Fazio, S | 1 |
| De Sarro, G | 1 |
| Bhattacharya, SK | 1 |
| Sen, AP | 1 |
| Upadhyay, SN | 1 |
| Jaiswal, AK | 1 |
| Cramer, JA | 1 |
| Arrigo, C | 1 |
| Van Hammée, G | 1 |
| Bromfield, EB | 1 |
| Radmayr, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Multicenter, Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam (LEV) (Oral Tablets of 166, 250 or 500 mg b.i.d.), at Individualized Doses up to a Maximum of 4000 mg/Day (or 80 mg/kg/Day for Children and Adolescents Less T[NCT00150748] | Phase 3 | 217 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy Of Levetiracetam Extended Release in Very Heavy Drinkers[NCT00970814] | Phase 2 | 130 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
based on self report (NCT00970814)
Timeframe: Study Weeks 5-14
| Intervention | drinks per day (Least Squares Mean) |
|---|---|
| Sugar Pill and BBCET | 6.3 |
| Levetiracetam and BBCET | 7.1 |
A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report. (NCT00970814)
Timeframe: Study Weeks 5-14
| Intervention | percentage of heavy drinking days (Least Squares Mean) |
|---|---|
| Sugar Pill and BBCET | 41.2 |
| Levetiracetam and BBCET | 45.8 |
A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report. (NCT00970814)
Timeframe: Weeks 5-14
| Intervention | percentage of subjects (Number) |
|---|---|
| Sugar Pill and BBCET | 18.2 |
| Levetiracetam and BBCET | 14.1 |
1 review available for piracetam and Anxiety
| Article | Year |
|---|---|
Presentation of opsoclonus myoclonus ataxia syndrome with glutamic acid decarboxylase antibodies.
Topics: Adult; Anticonvulsants; Anxiety; Ataxia; Autoantibodies; Diagnosis, Differential; Earache; Female; F | 2012 |
6 trials available for piracetam and Anxiety
| Article | Year |
|---|---|
A prospective pilot study of levetiracetam for body dysmorphic disorder.
Topics: Adult; Anticonvulsants; Anxiety; Body Image; Dose-Response Relationship, Drug; Female; Humans; Levet | 2009 |
Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study.
Topics: Adolescent; Adult; Anticonvulsants; Anxiety; Child; Child, Preschool; Depression; Dose-Response Rela | 2012 |
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.
Topics: Adult; Affect; Aged; Alcoholism; Anticonvulsants; Anxiety; Breath Tests; Delayed-Action Preparations | 2012 |
Piracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo.
Topics: Adult; Aged; Anxiety; Cognition Disorders; Coronary Artery Bypass; Double-Blind Method; Female; Huma | 2006 |
Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anticonvulsants; Anxiety; Drug Therapy, Combination; | 2000 |
[Modification of the decrease in efficiency in the middle period of life. Experiences with piracetam (Nootropil) in professional practice].
Topics: Adult; Age Factors; Aged; Anxiety; Clinical Trials as Topic; Drug Evaluation; Efficiency; Euphoria; | 1976 |
17 other studies available for piracetam and Anxiety
| Article | Year |
|---|---|
The differential effect of levetiracetam on memory and anxiety in rats.
Topics: Animals; Anticonvulsants; Anxiety; Levetiracetam; Male; Maze Learning; Piracetam; Rats; Rats, Wistar | 2022 |
[The influence of piracetam on behavior and brain receptors in C57BL/6 and BALB/c mice: nootropic and anxiolytic effects].
Topics: Animals; Anxiety; Behavior, Animal; Binding Sites; Cognition; Drug Administration Schedule; Frontal | 2013 |
Omega 3 polyunsaturated fatty acids enhance the protective effect of levetiracetam against seizures, cognitive impairment and hippocampal oxidative DNA damage in young kindled rats.
Topics: Animals; Anticonvulsants; Anxiety; Avoidance Learning; Cognition Disorders; Convulsants; DNA Damage; | 2015 |
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve | 2016 |
Dose-dependent effects of levetiracetam after hypoxia and hypothermia in the neonatal mouse brain.
Topics: Animals; Animals, Newborn; Anticonvulsants; Anxiety; Apoptosis; Behavior, Animal; Brain; Brain Injur | 2016 |
Impending status epilepticus and anxiety in a pregnant woman treated with levetiracetam.
Topics: Administration, Oral; Adult; Anticonvulsants; Anxiety; Epilepsy, Frontal Lobe; Fear; Female; Humans; | 2008 |
Levetiracetam-mediated emotional behavior in heterozygous rolling Nagoya Ca(V)2.1 channel mutant mice.
Topics: Animals; Anticonvulsants; Anxiety; Blotting, Western; Brain Stem; Calcium Channels, N-Type; Dopamine | 2010 |
Psychoimmunomodulatory effect of phenotropil in animals with immune stress.
Topics: Animals; Antibodies; Anxiety; Behavior, Animal; Hemagglutination Inhibition Tests; Hypersensitivity, | 2011 |
Anxiety and predisposition to audiogenic epilepsy in rats of different genotypes.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Benzimidazoles; Epilepsy, Reflex; Genetic Pr | 2011 |
Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy.
Topics: Adult; Anticonvulsants; Anxiety; Depression; Drug Therapy, Combination; Epilepsy; Female; Humans; Le | 2013 |
Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Benzodiazepines; Brain Neoplasms; Carbamazepine; Clobazam; Dr | 2012 |
Anxiolytic profile of the antiepileptic drug levetiracetam in the Vogel conflict test in the rat.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Conflict, Psychological; Electric Stimulatio | 2003 |
Ascorbic Acid: a promising memory-enhancer in mice.
Topics: Aging; Amnesia; Animals; Antioxidants; Anxiety; Ascorbic Acid; Avoidance Learning; Behavior, Animal; | 2003 |
Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study.
Topics: Adult; Anticonvulsants; Anxiety; Depression; Epilepsies, Partial; Female; gamma-Aminobutyric Acid; H | 2006 |
Psychic disturbances associated with sodium valproate plus levetiracetam.
Topics: Anticonvulsants; Anxiety; Drug Therapy, Combination; Epilepsies, Partial; Female; Humans; Levetirace | 2007 |
Anxiolytic activity of piracetam, a nootropic agent, following subchronic administration in rodents.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Brain; Diazepam; Isatin; Male; Mice; Monoamine Oxidase Inhibi | 1993 |
The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Chlordiazepoxide; Dose | 2002 |